12/18
08:45 am
bfri
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio
Medium
Report
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio
12/4
09:00 am
bfri
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities
Medium
Report
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities
12/2
09:06 am
bfri
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT [Yahoo! Finance]
Low
Report
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT [Yahoo! Finance]
12/2
08:45 am
bfri
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT
Low
Report
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT
11/14
12:15 pm
bfri
Biofrontera (NASDAQ:BFRI) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Medium
Report
Biofrontera (NASDAQ:BFRI) had its "buy" rating reaffirmed by analysts at Benchmark Co..
11/13
11:53 am
bfri
Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/13
08:15 am
bfri
Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update
Medium
Report
Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update
11/7
08:00 am
bfri
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
High
Report
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
11/6
04:01 pm
bfri
Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025
Medium
Report
Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025
10/30
12:25 pm
bfri
Biofrontera (NASDAQ:BFRI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Biofrontera (NASDAQ:BFRI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/23
08:45 am
bfri
Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG
Medium
Report
Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG
10/8
12:15 pm
bfri
Biofrontera (NASDAQ:BFRI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Biofrontera (NASDAQ:BFRI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/28
10:42 am
bfri
Biofrontera Inc. (NASDAQ:BFRI): When Will It Breakeven? [Yahoo! Finance]
Medium
Report
Biofrontera Inc. (NASDAQ:BFRI): When Will It Breakeven? [Yahoo! Finance]